Building on a foundation of thirty-three years of market leadership
In the ongoing rhythm of institutional renewal, Alcon has entrusted David Melki with the stewardship of its Vision Care operations across Spain and Portugal — a market shaped over thirty-three years by a single guiding hand. Melki arrives carrying two decades of experience navigating Europe's premium consumer landscape, now turned toward the more intimate terrain of eye health. The appointment speaks to a broader truth in business: that continuity and change are not opposites, but partners in the long work of building something lasting.
- After thirty-three years under one leader, Alcon's Iberian Vision Care division faces the delicate challenge of preserving hard-won market dominance while opening a new chapter.
- David Melki steps in with credentials forged at L'Oréal and luxury consumer brands, but must now translate that polish into the specialized language of eye care professionals and clinical relationships.
- The company is betting that Melki's European strategic accounts experience — where he rebuilt client engagement from transactional to collaborative — will translate directly into deeper partnerships with Iberian practitioners.
- Alcon is simultaneously pushing new technology into the market, with the Precision7 weekly lens promising comfort through its seventh day and an expanded Systane dry eye portfolio riding a wave of growing demand.
- The transition is framed deliberately as continuation rather than disruption, with Alcon positioning Melki as a builder upon Inés Mateu's foundation rather than a force of reinvention.
Alcon has appointed David Melki as the new head of its Vision Care franchise for Spain and Portugal, a role that carries the weight of a thirty-three-year legacy left by his predecessor, Inés Mateu. Her tenure defined Alcon's dominance in the Iberian contact lens and eye care market, and the company has been careful to frame Melki's arrival as an extension of that foundation rather than a break from it.
Melki brings more than two decades of leadership across Europe's premium consumer goods sector, with stints at L'Oréal, L'Occitane en Provence, and the Yves Rocher Group. He joined Alcon in 2020 as head of Strategic Accounts for Vision Care Europe, where he shifted the company's approach toward long-term, collaborative client relationships — a skill set now pointed squarely at the Iberian Peninsula.
In his first public statements, Melki emphasized strengthening ties with eye care professionals and advancing patient-centered solutions, signaling that relationship-building will be as central to his strategy as product innovation. That innovation is already in motion: Alcon's WaterInnovations lens family — including Dailies Total1, Total30, and Precision1 — has recently been joined by Precision7, a weekly lens engineered to sustain comfort through its seventh day of wear. The Systane dry eye portfolio is also expanding, responding to rising demand driven by screen exposure and environmental conditions.
With competition in Iberian eye care remaining intense, Alcon is positioning Melki's blend of consumer marketing instinct and professional relationship expertise as the formula for its next chapter in the region.
Alcon, the global eye care company, has named David Melki to lead its Vision Care business across Spain and Portugal, effective immediately. The appointment marks a significant transition for the company's Iberian operations, which have been shaped over three decades by his predecessor.
Melki arrives with a résumé built across Europe's premium consumer goods sector. He spent years in leadership roles at L'Oréal, L'Occitane en Provence, and the Yves Rocher Group, managing marketing, sales, and general management functions. He joined Alcon in 2020 as head of Strategic Accounts for Vision Care Europe, a position that gave him visibility across the continent and responsibility for reshaping how the company engaged with its largest clients. In that role, he orchestrated a shift toward deeper customer relationships, negotiating long-term partnerships and building collaborative programs that extended beyond transactional dealings.
The Iberian market holds particular strategic weight for Alcon. Spain and Portugal represent a dynamic region where eye care demand continues to grow, and Melki's appointment signals the company's intent to deepen its footprint there. In a statement, Melki framed the role as both an opportunity and a responsibility. He committed to strengthening ties with eye care professionals and advancing solutions that would benefit both practitioners and their patients. His language emphasized innovation and the importance of building on existing relationships rather than starting fresh.
Alcon's vision care portfolio has evolved considerably in recent years, anchored by its WaterInnovations contact lens family. The lineup includes Dailies Total1 for daily wear, Total30 for monthly use, and Precision1 for weekly replacement. More recently, the company introduced Precision7, a weekly lens engineered to deliver up to sixteen hours of comfort through its seventh day of use—a technical claim that addresses a persistent challenge in contact lens design, where comfort typically degrades as lenses age. Alongside these innovations, Alcon has expanded its Systane brand, which focuses on dry eye treatment and maintenance, a category that has grown as screen time and environmental factors drive increased prevalence of the condition.
Melki's appointment follows thirty-three years of leadership by Inés Mateu, whose tenure established Alcon's dominant position in the Spanish and Portuguese markets. The company credited Mateu's contributions as decisive in driving growth and delivering strong financial results. Her departure represents the end of an era, and Alcon framed Melki's arrival as a continuation of that success rather than a departure from it. The company emphasized that Melki would build on the foundation Mateu had constructed, suggesting continuity in strategy even as leadership changes.
The timing of the announcement reflects Alcon's broader commitment to innovation and professional education as core pillars of its market strategy. The company sees these elements, paired with cutting-edge technology, as essential to delivering superior patient outcomes. With Melki now in place, Alcon is positioned to push forward on both fronts across the Iberian Peninsula, where competition in eye care remains intense and differentiation through product quality and professional relationships remains paramount.
Citações Notáveis
Spain and Portugal represent a strategic environment for Alcon. It is a privilege to assume this new role in such a dynamic setting. I am committed to building solid relationships with eye care professionals and advancing innovative solutions that improve the experience of both patients and practitioners.— David Melki, new Vision Care franchise head
A Conversa do Hearth Outra perspectiva sobre a história
Why does this appointment matter beyond a routine leadership change?
Because Melki is stepping into a market where Alcon has been dominant for three decades, and that kind of transition—from a leader who built something to someone inheriting it—can either accelerate momentum or disrupt it. The company is betting he can do the former.
What's his actual track record with the company?
He's been there since 2020, so he's not an outsider. He spent six years reshaping how Alcon works with its biggest clients across Europe. That's not glamorous work, but it's foundational. It means he understands the business from the inside.
The source mentions innovation a lot. Is that just corporate language, or is there something real happening?
There's something real. They're releasing new contact lenses with specific performance claims—like a weekly lens that stays comfortable on day seven. That's a technical problem they're solving. The dry eye care portfolio is also expanding into a category that's growing because of how people live now.
What about Inés Mateu? Is her departure significant?
Thirty-three years is a long tenure. She built the foundation Melki is inheriting. The company is careful to frame this as continuity, not rupture, but losing someone that embedded is always a moment of vulnerability.
What should we watch for in the coming months?
Whether Melki can maintain the relationships Mateu built while introducing his own strategic priorities. And whether Alcon's innovation pipeline—the new lenses, the expanded Systane line—actually resonates with eye care professionals and patients in Spain and Portugal.